US20160200814A1 - Immunoreceptor modulation for treating cancer and viral infections - Google Patents

Immunoreceptor modulation for treating cancer and viral infections Download PDF

Info

Publication number
US20160200814A1
US20160200814A1 US14/913,347 US201314913347A US2016200814A1 US 20160200814 A1 US20160200814 A1 US 20160200814A1 US 201314913347 A US201314913347 A US 201314913347A US 2016200814 A1 US2016200814 A1 US 2016200814A1
Authority
US
United States
Prior art keywords
cells
mammal
inhibitory agent
antibody
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/913,347
Other languages
English (en)
Inventor
Mark Smythe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903189A external-priority patent/AU2013903189A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of US20160200814A1 publication Critical patent/US20160200814A1/en
Assigned to THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH reassignment THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SMYTH, MARK
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the method relieves immune inhibition and/or enhances or restores immune surveillance in the mammal to thereby treat or prevent a viral infection in the mammal.
  • the CD96-inhibitory agent is an anti-cancer agent.
  • mice The binding of mouse CD155-Fc coupled with AF-647 to purified NK cells freshly isolated from WT, CD96 ⁇ / ⁇ , DNAM-1 ⁇ / ⁇ or DNAM-1 ⁇ / ⁇ CD96 ⁇ / ⁇ mice was assessed at the indicated concentrations by flow cytometry.
  • FIG. 6 Enhanced anti-tumor responses of Doxorubicin (DOX) chemotherapy with host CD96 deficiency.
  • C57BL/6 wild type (WT), DNAM-1 ⁇ / ⁇ , and CD96 ⁇ / ⁇ mice were injected subcutaneously with AT3-OVA dim tumor cells (10 6 cells) and treated on day 16 with control PBS or DOX (50 microliters, 2 mM, intratumor). Means ⁇ standard errors of 5 mice per group (mm 2 ) are shown.
  • FIG. 9 Late anti-CD96 mAb enhances anti-tumor responses generated by anti-PD-1 mAb.
  • C57BL/6 wild-type (WT) mice were injected subcutaneously with B16-OVA melanoma cells (10 5 cells) and treated on day 16, 20, and 24 with intraperitoneal injections of anti-CD96 mAb (3.3, 250 ⁇ g i.p), anti-PD-1 mAb (RMP1-14, 250 ⁇ g i.p.), anti-CTLA-4 (UC10-4F10, 250 ⁇ g i.p.), anti-CD96/anti-PD-1 mAbs (250 ⁇ g i.p each), anti-CD96/anti-CTLA-4 mAbs (250 ⁇ g i.p each) or control Ig (cIg) (2A3, 250 ⁇ g i.p). Means ⁇ SEM of 5 mice per group (mm 2 ) are shown (*: p ⁇ 0.05 compared with anti-CD96 alone by Mann-Whitney test
  • FIG. 13 Anti-CD96 suppresses B16F10 lung metastasis, alone and in combination with T cell checkpoint blockade.
  • C57BL/6 wild type (WT) mice were injected intravenous with B16F10 melanoma cells (10 5 cells).
  • the CD96-inhibitory agent inhibits, blocks or antagonizes a binding interaction between CD96 and CD155.
  • the CD96-inhibitory agent may bind to an extracellular domain of CD96, or a portion thereof, that is capable of interacting with CD155 (e.g. binding CD155 or being bound by CD155) to thereby at least partly inhibit or block CD96 binding to CD155.
  • isoform 1 of CD96 comprises the ITIM sequence IKYTCI wherein Y is residue 566.
  • preventing or “prevent” or “prevention” refers to a prophylactic treatment initiated prior to the onset of a symptom of a disease or condition that is responsive to at least partly blocking CD96-mediated immune inhibition, suppression or peripheral tolerance, so as to at least partly or temporarily prevent the occurrence of the symptom.
  • the CD96-inhibitory agent may be formulated alone or together with the one or more other agents is in the form of a pharmaceutical composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US14/913,347 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections Abandoned US20160200814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903189A AU2013903189A0 (en) 2013-08-22 Immunomodulator
AU2013903189 2013-08-22
PCT/AU2013/001132 WO2015024042A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections

Publications (1)

Publication Number Publication Date
US20160200814A1 true US20160200814A1 (en) 2016-07-14

Family

ID=52482821

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/913,347 Abandoned US20160200814A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections

Country Status (12)

Country Link
US (1) US20160200814A1 (enExample)
EP (1) EP3036255A4 (enExample)
JP (1) JP2016530267A (enExample)
KR (1) KR20160055818A (enExample)
CN (1) CN105636983A (enExample)
AU (1) AU2013398294A1 (enExample)
BR (1) BR112016003528A8 (enExample)
CA (1) CA2921772A1 (enExample)
HK (1) HK1225395A1 (enExample)
MX (1) MX2016002265A (enExample)
SG (1) SG11201601285XA (enExample)
WO (1) WO2015024042A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US10912831B1 (en) 2016-12-07 2021-02-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11555073B2 (en) 2018-12-20 2023-01-17 23Andme, Inc. Anti-CD96 antibodies and methods of use thereof
CN116377061A (zh) * 2022-11-28 2023-07-04 中山大学孙逸仙纪念医院 乳腺癌新辅助化疗耐药标志物及其应用
US20230212284A1 (en) * 2019-10-30 2023-07-06 University Of Tsukuba Immune Response Suppressor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CN110168078B (zh) * 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
MX2020001637A (es) * 2017-08-11 2020-08-20 Blink Biomedical Sas Agentes de union a cd96 como inmunomoduladores.
EP3712170A4 (en) 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
AU2020355614B2 (en) * 2019-09-27 2024-12-05 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
CN1777622A (zh) * 2003-02-24 2006-05-24 施里昂药品股份公司 脊髓灰质炎病毒受体功能的调节
WO2005107799A1 (ja) * 2004-05-06 2005-11-17 Eisai R & D Management Co., Ltd. 抗Necl-5抗体を有効成分として含む癌治療剤
WO2008073316A2 (en) * 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2009126688A2 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US9149544B2 (en) * 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
CN102204901A (zh) * 2010-03-30 2011-10-05 中国科学院上海生命科学研究院 调节免疫分子的试剂和方法
SG11201601283PA (en) * 2013-08-22 2016-03-30 Queensland Inst Med Res Immunoreceptor modulation for treating cancer and viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Byers, T. (CA Cancer Journal, 1999, 49: 353-361) *
Dennis (Nature. 2006 Aug 7; 442: 739-741) *
Fuchs et al. (J Immunol, 2004, 172: 3994-3998) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US10479833B2 (en) 2015-05-29 2019-11-19 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11267889B2 (en) 2015-05-29 2022-03-08 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US12492257B2 (en) 2015-05-29 2025-12-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US10912831B1 (en) 2016-12-07 2021-02-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11638755B2 (en) 2016-12-07 2023-05-02 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US12246066B2 (en) 2016-12-07 2025-03-11 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11555073B2 (en) 2018-12-20 2023-01-17 23Andme, Inc. Anti-CD96 antibodies and methods of use thereof
US12365732B2 (en) 2018-12-20 2025-07-22 23Andme, Inc. Anti-CD96 antibodies and methods of use thereof
US20230212284A1 (en) * 2019-10-30 2023-07-06 University Of Tsukuba Immune Response Suppressor
CN116377061A (zh) * 2022-11-28 2023-07-04 中山大学孙逸仙纪念医院 乳腺癌新辅助化疗耐药标志物及其应用

Also Published As

Publication number Publication date
EP3036255A1 (en) 2016-06-29
BR112016003528A8 (pt) 2018-01-30
MX2016002265A (es) 2016-12-16
AU2013398294A1 (en) 2016-03-17
HK1225395A1 (zh) 2017-09-08
EP3036255A4 (en) 2017-03-22
CA2921772A1 (en) 2015-02-26
WO2015024042A1 (en) 2015-02-26
SG11201601285XA (en) 2016-03-30
KR20160055818A (ko) 2016-05-18
JP2016530267A (ja) 2016-09-29
CN105636983A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
US20210047403A1 (en) Immunoreceptor modulation for treating cancer and viral infections
AU2013398294A1 (en) Immunoreceptor modulation for treating cancer and viral infections
US10302653B2 (en) Distinguishing antagonistic and agonistic anti B7-H1 antibodies
JP7026169B2 (ja) 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
US11718679B2 (en) CD137 antibodies and PD-1 antagonists and uses thereof
Akkaya et al. Dissection of agonistic and blocking effects of CD200 receptor antibodies
CN120359243A (zh) Lilrb2抗体产物和方法
KR20220034807A (ko) Cd38에 대해 특이성을 갖는 항체 및 이의 용도
US12195545B2 (en) Anti-OX40 monoclonal antibody and application thereof
AU2014308552B2 (en) Immunoreceptor modulation for treating cancer and viral infections
KR20250113410A (ko) 자가면역 장애에 대한 환자 선택 및 치료 모니터링
Saha Targeting the TIGIT/CD226/CD96 signaling Axis using the IgV domain of PVR
US20240000932A1 (en) Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
BRPI0616438A2 (pt) proteÍna, polinucleotÍdeo, anticorpo contra uma proteÍna secretora ou de membrana, ou um fragmento funcional do mesmo, hibridoma, agente terapÊutico para uma doenÇa autoimune, agente para inibir adesço de cÉlulas t, e, mÉtodo para triar uma substÂncia
WO2025220689A1 (ja) Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体
Tuomela The effect of radiotherapy on the susceptibility of cancer cells to natural killer cell cytotoxicity
EP4652197A1 (en) Therapeutic antibodies
WO2020080298A1 (ja) 樹状細胞の成熟抑制剤及び成熟抑制方法、並びに医薬組成物

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SMYTH, MARK;REEL/FRAME:043319/0607

Effective date: 20170427

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION